The President and CEO of Theralase joins us to discuss the outlook for 2017 in terms of the cancer and therapeutic divisions. The Company is starting to enroll its first patients for the clinical trial. This is a huge step for Theralase that will first test the safety and tolerability of the treatment.
We also discuss the sales of the therapeutic division and the TLC-2000 laser. Sales were steadily increasing throughout the year. Roger shares the revenue strategy that is slightly different this year. It is shaping up to be a big year for Theralase and Roger’s team.
Click here to visit the Theralase website for more information on the two divisions.
Click download link to listen on this device: Download Show